• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regressi

Mary Wilson

Well-known member
Published:November 26, 2021

DOI: https://doi.org/10.1016/j.cmi.2021.11.008

Bradley J. Langford, BScPhm, PharmD, Miranda So, BScPhm, PharmD, MPH, Valerie Leung, BScPhm, MBA, Sumit Raybardhan, BScPhm, MPH, Jennifer Lo, BScPhm, PharmD, Tiffany Kan, BScPhm, PharmD,
Felicia Leung, HBSc, Duncan Westwood, BA, Nick Daneman, MD, MSc, Derek R. MacFadden, MD, ScD,
Jean-Paul R. Soucy, MSc

Abstract

Objective

To identify risk factors and microbiology associated with respiratory and bloodstream bacterial infection in patients with COVID-19.

Methods

Data Sources: We searched MEDLINE, OVID Epub and EMBASE for published literature up to February 5, 2021. Study eligibility criteria:Studies including at least 50 patients with COVID-19 in any healthcare setting. Assessment of risk of Bias: We used a validated 10-item risk of bias tool for disease prevalence Methods of data synthesis: The main outcome of interest was the proportion of COVID-19 patients with bloodstream and/or respiratory bacterial co-infection and secondary infection. We performed meta-regression to identify study population factors associated with bacterial infection including healthcare setting, age, comorbidities and COVID-19 medication.

Results

Out of 33,345 studies screened, 171 were included in the final analysis. Bacterial infection data were available from 171,262 patients. The prevalence of co-infection was 5.1% (95% CI: 3.6% to 7.1%) and secondary infection was 13.1% (95% CI: 9.8% to 17.2%). There was a higher odds of bacterial infection in studies with a higher proportion of patients in the intensive care unit (ICU) (adjusted OR 18.8, 95% CI: 6.5 to 54.8). Female sex was associated with a lower odds of secondary infection (adjusted OR 0.73, 95% CI: 0.55 to 0.97) but not co-infection (adjusted OR 1.05, 95% CI: 0.80 to 1.37). The most common organisms isolated included Staphylococcus aureus, coagulase-negative Staphylococci, and Klebsiella species.

Conclusions

While the odds of respiratory and bloodstream bacterial infection are low in patients with COVID-19, meta-regression revealed potential risk factors for infection, including ICU setting and mechanical ventilation. The risk for secondary infection is substantially greater than the risk for co-infection in patients with COVID-19. Understanding predictors of co-infection and secondary infection may help to support improved antibiotic stewardship in patients with COVID-19.

https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00636-4/fulltext
 
Back
Top Bottom